ProbENCT07100743
Trial of Multi-Strain Probiotic Supplementation (Hexbio®) in Malaysian Patients With Drug-Resistant Epilepsy (ProbE)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary endpoint(s) modified Show 5 more changesShow less
- Eligibility criteria expanded, about 14 words
- Trial completed
- Secondary endpoint revised
- Study description expanded, about 17 words
- Collaborator revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (1)
Arms and interventions
HEXBIO MCP Granule probiotic is prepared in sachets which consist of the following probiotics: Lactobacillus acidophilus (BCMC 1 12130)107mg, Lactobacillus casei (BCMC 1 12313) -107mg, Lactobacillus lactis (BCMC 1 12451)-107 mg, (BCMC 1 02290) -107mg, Bifidobacterium infantis (BCMC 1 02129) -107mg and Bifidobacterium longum (BCMC 102120)-107mg. Patients will be instructed to consume one sachet directly before meal (drink water if needed) twice daily, for two months.
The placebo sachets will contain the same ingredient as the probiotic sachet but without the Lactobacillus sp. and Bifidobacterium sp. Participants in the placebo group will receive an identical Hexbio sachet (aluminum foil sachet.) with non-microbial material.
Dietary supplements: Probiotic Agent, Placebo
Sites
1 site in 1 country
- National University of MalaysiaKuala Lumpur, Malaysia